D
LIVE

Serial Number

79175767

Owner

DOMPE' FARMACEUTICI S.P.A

Attorney

Kristen McCallion

Filing Date

Dec 29, 2014

Add to watchlist:

No watchlists yet
View on USPTO

D Trademark

Serial Number: 79175767 • Registration: 5293325

D is a trademark filed by DOMPE' FARMACEUTICI S.P.A on December 29, 2014. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

DOMPE' FARMACEUTICI S.P.A (24 trademarks)

MILANO , IT

Entity Type: 03

Trademark Details

Filing Date

December 29, 2014

Registration Date

September 26, 2017

Published for Opposition

November 8, 2016

Goods & Services

[ Entertainment television news programme services in the field of pharmaceutical products and sanitary preparations for medical purposes broadcast over the internet; organizing community festivals featuring primarily pharmaceutical exhibition for medical purposes; arranging professional workshop and training courses in the field of pharmaceutical products and medicine for medical purposes; training services in the field of pharmaceutical and sanitary preparations for medical purposes; education service, namely, providing tutoring in the field of pharmaceutical and sanitary preparations for medical purposes; providing information relating to organizing community cultural activities and contests ]

[Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceuticals; gelatin capsules sold empty for pharmaceuticals;] ocular pharmaceuticals; pharmaceutical products for ophthalmological use [ ; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases also rare; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in tissue and organ transplantation also rare; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for treating diabetes also rare; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; sanitary preparations for medical purposes; all-purpose disinfectants ]

Conducting early evaluations in the field of new pharmaceuticals; conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology, treatment of cancer, diabetes, analgesic preparations, nerve grow factors, oncology, organ transplantation, antibiotics, respiratory diseases, bone diseases, rare diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, medical diagnostics, drug development and pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; research and development of pharmaceuticals for the treatment of cancer, diabetes, respiratory diseases, bone diseases, rare diseases, ocular disorders and diseases; research and development in the pharmaceutical and biotechnology fields

Filing History

INTERNATIONAL REGISTRATION RENEWED
Jan 2, 2025 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
May 23, 2024 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
May 23, 2024 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 20, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Sep 26, 2023 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sep 26, 2022 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 4, 2021 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Feb 12, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 26, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 29, 2017 FICS
FINAL DISPOSITION PROCESSED
Dec 29, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 26, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 26, 2017 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Aug 21, 2017 TMBN
OPPOSITION TERMINATED NO. 999999
Aug 21, 2017 OP.T
OPPOSITION DISMISSED NO. 999999
Aug 21, 2017 OP.D
REFUSAL PROCESSED BY IB
Jun 3, 2017 RFNT
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 12, 2017 OPNX
OPPOSITION INSTITUTED NO. 999999
May 10, 2017 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
May 9, 2017 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
May 9, 2017 OPNC
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 5, 2017 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 5, 2017 OPNR
EXTENSION OF TIME TO OPPOSE RECEIVED
Dec 7, 2016 ETOF
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 18, 2016 OPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 8, 2016 NPUB
PUBLISHED FOR OPPOSITION
Nov 8, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 19, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 19, 2016 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 19, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 28, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 28, 2016 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 28, 2016 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 30, 2016 GNFN
FINAL REFUSAL E-MAILED
Jun 30, 2016 GNFR
FINAL REFUSAL WRITTEN
Jun 30, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 1, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 1, 2016 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Apr 28, 2016 NREP
REFUSAL PROCESSED BY IB
Dec 18, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 1, 2015 RFCS
REFUSAL PROCESSED BY MPU
Dec 1, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 26, 2015 RFCR
NON-FINAL ACTION WRITTEN
Nov 25, 2015 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 14, 2015 MAFR
ASSIGNED TO EXAMINER
Nov 10, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 10, 2015 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 9, 2015 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 7, 2015 REPR